Fleqsuvy (baclofen) vs Briumvi (ublituximab-xiiy)
Fleqsuvy (baclofen) vs Briumvi (ublituximab-xiiy)
Fleqsuvy (baclofen) is a muscle relaxer and an antispastic agent used to treat muscle symptoms caused by multiple sclerosis, including spasm, pain, and stiffness, whereas Briumvi (ublituximab-xiiy) is a monoclonal antibody designed to target CD20-positive B cells and is used for the treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of relapse and slow the progression of the disease. Baclofen is typically taken orally and acts on the central nervous system to relieve spasticity without directly affecting muscle strength, making it suitable for symptom management in MS. In contrast, Briumvi is administered intravenously and works by modulating the immune system, which is more appropriate for patients seeking a disease-modifying therapy to actively manage the course of their MS.
Difference between Fleqsuvy and Briumvi
| Metric | Fleqsuvy (baclofen) | Briumvi (ublituximab-xiiy) |
|---|---|---|
| Generic name | Baclofen | Ublituximab-xiiy |
| Indications | Spasticity, muscle spasms | Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL) |
| Mechanism of action | GABA-B receptor agonist | CD20-directed cytolytic antibody |
| Brand names | Fleqsuvy | Briumvi |
| Administrative route | Oral, intrathecal | Infusion |
| Side effects | Drowsiness, dizziness, weakness, nausea | Infusion reactions, neutropenia, diarrhea, fatigue |
| Contraindications | Hypersensitivity to baclofen, severe kidney impairment | Hypersensitivity to ublituximab-xiiy, active, severe infections |
| Drug class | Muscle relaxant, antispastic agent | Monoclonal antibody, anti-CD20 |
| Manufacturer | Varies by generic manufacturer | TG Therapeutics |
Efficacy
Fleqsuvy (Baclofen) and Its Efficacy in Multiple Sclerosis (MS)
Fleqsuvy, a brand name for baclofen, is a medication that is primarily used to treat spasticity, a common symptom in patients with Multiple Sclerosis (MS). Spasticity is characterized by muscle stiffness and involuntary muscle spasms, which can be painful and limit mobility. Baclofen acts as a muscle relaxant by activating GABA-B receptors, which inhibits the excitatory neurotransmitters that cause muscle spasticity. While baclofen is not a cure for MS, it can significantly improve the quality of life for patients by reducing the severity of spasticity-related symptoms.
The efficacy of baclofen in managing spasticity in MS has been supported by numerous studies. It is considered a first-line treatment for this symptom and is often effective in reducing the frequency and intensity of muscle spasms. However, the response to baclofen can vary among individuals, and the optimal dosage may need to be adjusted to balance the therapeutic effects with potential side effects. Some patients may experience relief with lower doses, while others may require higher doses for adequate symptom control.
Briumvi (Ublituximab-xiiy) and Its Efficacy in Multiple Sclerosis (MS)
Briumvi, known generically as ublituximab-xiiy, is a monoclonal antibody that has been studied for its potential use in treating Multiple Sclerosis (MS). Ublituximab-xiiy targets a specific protein called CD20 found on the surface of B cells, which are a type of immune cell implicated in the pathogenesis of MS. By depleting these B cells, Briumvi aims to modulate the immune response and reduce the inflammatory processes that contribute to the demyelination and neuronal damage characteristic of MS.
The efficacy of Briumvi in treating MS is currently being evaluated in clinical trials. Preliminary results have shown promise, with some studies reporting a reduction in the annualized relapse rate among patients with relapsing forms of MS. Additionally, ublituximab-xiiy has demonstrated potential in reducing new or enlarging brain lesions on MRI scans, which are indicative of disease activity. While the full extent of Briumvi's benefits and its long-term efficacy in MS are still under investigation, these initial findings suggest that it may offer a new therapeutic option for managing this chronic condition.
Regulatory Agency Approvals
Fleqsuvy
-
Food and Drug Administration (FDA), USA
Briumvi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Fleqsuvy or Briumvi today
If Fleqsuvy or Briumvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us